Akari Therapeutics
AKTXAkari Therapeutics, PLC (NASDAQ: AKTX) is a clinical-stage biopharmaceutical company based in the United Kingdom. The company's primary business focus is the development of therapeutics designed to inhibit acute and chronic inflammation. Its research and development efforts are centered on targeting two specific biological pathways: the complement system and the leukotriene system, which are recognized mediators of inflammatory processes. The company's lead asset is nomacopan, a bispecific recombinant inhibitor that simultaneously targets complement component C5 and leukotriene B4 (LTB4). This dual mechanism of action is being investigated for the treatment of rare inflammatory diseases with significant unmet medical need. Akari's clinical-stage programs include development in hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) and bullous pemphigoid, a rare autoimmune skin disorder. As a publicly traded entity, Akari Therapeutics operates within the biotechnology and rare disease sectors. Its activities are concentrated on advancing nomacopan through clinical trials to evaluate safety and efficacy in its targeted indications. The company's strategic focus remains on progressing its clinical pipeline for inflammatory conditions mediated by the complement and leukotriene pathways.
AKTX · Stock Price
Historical price data
About
Akari Therapeutics, PLC (NASDAQ: AKTX) is a clinical-stage biopharmaceutical company based in the United Kingdom. The company's primary business focus is the development of therapeutics designed to inhibit acute and chronic inflammation. Its research and development efforts are centered on targeting two specific biological pathways: the complement system and the leukotriene system, which are recognized mediators of inflammatory processes. The company's lead asset is nomacopan, a bispecific recombinant inhibitor that simultaneously targets complement component C5 and leukotriene B4 (LTB4). This dual mechanism of action is being investigated for the treatment of rare inflammatory diseases with significant unmet medical need. Akari's clinical-stage programs include development in hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) and bullous pemphigoid, a rare autoimmune skin disorder. As a publicly traded entity, Akari Therapeutics operates within the biotechnology and rare disease sectors. Its activities are concentrated on advancing nomacopan through clinical trials to evaluate safety and efficacy in its targeted indications. The company's strategic focus remains on progressing its clinical pipeline for inflammatory conditions mediated by the complement and leukotriene pathways.